Skip to main content

Erasmus to Use Illumina's 610-Quad BeadChips in Fetal Abnormality Study

NEW YORK (GenomeWeb News) — The Erasmus Medical Center will use Illumina’s BeadChips in a 10,000-subject study aimed at identifying early environmental and genetic causes of abnormal growth in fetal development, Illumina said today.
 
The Rotterdam, Netherlands-based research hospital has bought Illumina’s Infinium HD Human610-Quad BeadChips for the Generation R Study, which is backed in part by the Dutch government, industry partners, and the hospital.
 
Erasmus used Illumina’s HumanHap 550 BeadChip in a similar study of 10,000 individuals that was focused on late-age disease development, according to Andre Uitterlinden, from the hospital’s Internal Medicine department. The latest BeadChip will allow researchers to boost their throughput four times compared to the 550, he added.
 
Illumina said the 610-Quad, in addition to its extra 60,000 genetic markers, also includes proprietary CNV content the company developed through a collaboration with Decode Genetics.
 
Financial terms of the agreement were not released.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.